FdaApplication
BLA 761128
Identifiers
- fda_app_no: BLA761128
Properties
| Property | Value |
|---|---|
| applicant_name | Novartis Pharmaceuticals Corporation |
| application_type | BLA |
| approval_date | 2019-11-15 |
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ADAKVEO | CRIZANLIZUMAB-TMCA | 100MG/10ML (10MG/ML) | INJECTABLE;INJECTION |
1 product